Litcius/Paper detail

Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial

Claire Dahyot‐Fizelier, Sigismond Lasocki, Thomas Kerforne, Pierre-Francois Perrigault, Thomas Geeraerts, Karim Asehnoune, Raphaël Cinotti, Yoann Launey, Vincent Cottenceau, M. Laffon, Thomas Gaillard, Matthieu Boisson, Camille Aleyrat, Denis Frasca, Olivier Mimoz, Claire Dahyot‐Fizelier, Sigismond Lasocki, Thomas Kerforne, Pierre-Francois Perrigault, Thomas Geeraerts, Karim Asehnoune, Raphaël Cinotti, Yoann Launey, Vincent Cottenceau, M. Laffon, Thomas GAILLARD, Matthieu BOISSON, Camille Aleyrat, Denis Frasca, Olivier MIMOZ, Clément Guyonnaud, Rémy Bellier, Thierry Bénard, Elsa Carise, Franck Petitpas, Hodanou Nanadoumgar, Nadia IMZI, Sabrina Seguin, Karine Garnier, Véronique FERRAND-RIGALLAUD, Séverine CLERJAUD, Soizic Gergaud, Flora Djanikian, Kévin Chalard, Ségolène Mrozek, Sylvain PANH, Antoine Roquilly, Bertrand Rozec, Philippe Séguin, Yannick MALLEDANT, Djilali Elaroussi, Martine Ferrandière, Matthieu Biais, Martine Ferrandière, Matthieu Biais

2024The Lancet Respiratory Medicine69 citationsDOI

Topics & Concepts

MedicinePlaceboCeftriaxonePneumoniaVentilator-associated pneumoniaDouble blindRandomized controlled trialIntensive care medicineInternal medicineAlternative medicineAntibioticsPathologyBiologyMicrobiologyNosocomial Infections in ICUAntibiotic Resistance in BacteriaSepsis Diagnosis and Treatment
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial | Litcius